To retrospectively evaluate the magnetic resonance (MR) imaging findings of "triple-negative" breast cancer (ie, cancer that is estrogen receptor [ER] negative, progesterone receptor [PR] negative, and human epidermal growth factor receptor 2 [HER2] negative) and to compare them with those of breast cancers that are ER positive, PR positive, and HER2 negative. Institutional review board approval and informed consent were obtained. The MR imaging findings in 176 randomly assigned women (mean age, 56 years; range, 29-87 years) with surgically confirmed triple-negative breast cancers (n = 59) or ER-positive/PR-positive/HER2-negative breast cancers (n = 117) were reviewed. MR imaging findings included tumor shape, margin, internal enhancement, and size, as well as intratumoral signal intensity that was stronger than or almost the same as that of water or vessels on T2-weighted MR images. The MR imaging findings were compared with the pathologic findings. High histologic grade (P < .001), unifocal lesion (P = .012), mass lesion type (P < .001), smooth mass margin (P = .001), rim enhancement (P < .001), persistent enhancement pattern (P = .005), and very high intratumoral signal intensity on T2-weighted MR images (P = .002) were significantly associated with triple-negative breast cancer. Very high intratumoral signal intensity on T2-weighted MR images was significantly associated with intratumoral necrosis (P < .001). Several MR imaging features might be used for detecting triple-negative breast cancer.
OBJECTIVE. The purpose of our study was to evaluate the efficacy of FDG PET and bone SPECT for diagnosing bone metastases in breast cancer.SUBJECTS AND METHODS. The study was a prospective series of 15 patients with breast cancer who underwent both PET and bone scanning with SPECT. Comparison was performed on a lesion-by-lesion analysis. MDCT, MRI, and the patient's clinical course were used as references.RESULTS. In the lesion-by-lesion analysis (n = 900), the sensitivity for diagnosing bone metastases was 85% for SPECT and 17% for PET, specificity was 99% for SPECT and 100% for PET, and accuracy was 96% for SPECT and 85% for PET. In the statistical analysis, bone SPECT was significantly superior to FDG PET for its sensitivity (p < 0.0001) and accuracy (p < 0.0001). No statistically significant difference was seen with regard to specificity. When classifying the bone metastases as osteoblastic or osteolytic, bone scanning classified 92% of metastases as osteoblastic and 35% of metastases as osteolytic, w...
12 January 2008 in Breast Cancer Research and Treatment